Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LDR + Immunochemotherapy in Gastric Cancer With Peritoneal Carcinomatosis
NCT07784413Phase 2Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Sep 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
A Phase 2 trial of serplulimab, bevacizumab, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, Paclitaxel Micelles for Injection in gastric cancer (GC), sponsored by Zhejiang Cancer Hospital. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
serplulimabbevacizumabirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabPaclitaxel Micelles for Injection
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT07784413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07784413.